J Cancer 2016; 7(15):2309-2316. doi:10.7150/jca.16622 This issue Cite

Research Paper

Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer

Bo Chen1,*, Danian Dai1,*, Hailin Tang1,*, Xi Chen2, Xiaohong Ai3, Xiaojia Huang1, Weidong Wei1✉, Xiaoming Xie1✉

1. Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
2. Department of Anatomy, Medical College, University of South China, Hengyang, Hunan Province, China.
3. Department of Radiotherapy, The First Affiliated Hospital, University of South China, Hengyang, Hunan Province, China.
* B. Chen, D. Dai and H. Tang contributed equally to this work.

Citation:
Chen B, Dai D, Tang H, Chen X, Ai X, Huang X, Wei W, Xie X. Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer. J Cancer 2016; 7(15):2309-2316. doi:10.7150/jca.16622. https://www.jcancer.org/v07p2309.htm
Other styles

File import instruction

Abstract

Background: Serum parameters as prognostic parameters are studied widely. We aim to examine the prognostic significance of the serum alkaline phosphatase (ALP) level and lactate dehydrogenase (LDH) level in triple negative breast cancer (TNBC).

Methods: Total of 253 TNBC patients from Sun Yat-sen University Cancer Center who underwent treatment between January 2004 and December 2009 was conducted in this retrospective study. Before treatment serum ALP and LDH levels were routinely measured. We use the receiver operating characteristic (ROC) curve analysis to estimate the cutoff value of serum ALP and LDH levels. The Kaplan-Meier method and multivariable Cox regression analysis were used for Disease free survival (DFS) and overall survival (OS) assessed.

Results: The ROC curves determined that the optimum cutoff point for ALP and LDH were 66.5u/L and 160.5u/L, respectively. The elevated ALP and LDH were both significantly associated with decreased DFS and OS (both P < 0.001). In addition, the entire cohort was stratified into three subgroups basis of ALP levels and LDH levels. TNBC Patients who with ALP >66.5 u/L and LDH >160.5u/L had the worst DFS and OS (both P < 0.001). In TNBC patients, univariate and multivariate Cox regression analyses conformed ALP and LDH were independent unfavorable prognostic factors for DFS and OS.

Conclusions: The serum levels of ALP and LDH before treatment are independent prognostic parameters and may serve as complement to help predict survival in TNBC.

Keywords: Alkaline phosphatase, Lactate dehydrogenase, Triple negative breast cancer, Prognostic factor, Biomarker.


Citation styles

APA
Chen, B., Dai, D., Tang, H., Chen, X., Ai, X., Huang, X., Wei, W., Xie, X. (2016). Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer. Journal of Cancer, 7(15), 2309-2316. https://doi.org/10.7150/jca.16622.

ACS
Chen, B.; Dai, D.; Tang, H.; Chen, X.; Ai, X.; Huang, X.; Wei, W.; Xie, X. Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer. J. Cancer 2016, 7 (15), 2309-2316. DOI: 10.7150/jca.16622.

NLM
Chen B, Dai D, Tang H, Chen X, Ai X, Huang X, Wei W, Xie X. Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer. J Cancer 2016; 7(15):2309-2316. doi:10.7150/jca.16622. https://www.jcancer.org/v07p2309.htm

CSE
Chen B, Dai D, Tang H, Chen X, Ai X, Huang X, Wei W, Xie X. 2016. Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer. J Cancer. 7(15):2309-2316.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image